Simcere Pharmaceutical Group Limited announced that, on March 9, 2024, the Investigational New Drug application of SIM0500, a humanized GPRC5D-BCMA-CD3 trispecific antibody, which is a new investigational anti-tumor drug independently developed by the Group, has been approved by the U.S. Food and Drug Administration. SIM0500 is intended to be investigated in a clinical trial in patients with relapsed or refractory multiple myeloma. In addition, the IND application of SIM0500 in China was accepted by the National Medical Products Administration (Guo Jia Yao Pin Jian Du Guan Li Ju) of China on January 2, 2024.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
5.77 HKD | -0.69% | -0.17% | -14.26% |
EPS Revisions
Annual profits - Rate of surprise
1st Jan change | Capi. | |
---|---|---|
-14.26% | 1.89B | |
+20.39% | 43.67B | |
+26.21% | 22.79B | |
+21.43% | 15.45B | |
+18.82% | 14.29B | |
+53.37% | 12.83B | |
-0.05% | 6.79B | |
-11.88% | 6.52B | |
-8.87% | 5.73B | |
+12.62% | 5.59B |
- Stock Market
- Equities
- 2096 Stock
- News Simcere Pharmaceutical Group Limited
- Simcere Pharmaceutical Group Limited Announces Approval of the Investigational New Drug for SIM0500